COMPARATIVE STUDY OF EFFICIENCY AND SAFETY OF THE NEW DRUG OF AMLODOPINE – S-AMLODOPINE IN PATIENTS WITH ARTERIAL HYPERTENSION OF I-II DEGREE
https://doi.org/10.20996/1819-6446-2008-4-2-34-37
Abstract
Aim. To evaluate efficacy and safety of a new drug of amlodipine – S-amlodipine (Azomex, Emcur, India) compared to original drug of racemic amlodipine (Norvasc, Pfizer, USA) in patients with arterial hypertension (HT) of I-II grade.
Material and methods. 39 patients with HT of I-II grade were randomized into two groups and took drugs of amlodipine during 8 weeks. Ambulatory blood pressure monitoring (ABPM) was undertaken before treatment and at the end of treatment.
Results. 34 patients completed 8-week therapy. Both drugs showed antihypertensive effect: significant decrease in average levels of systolic and diastolic blood pressure (BP) recorded by office and ABPM measurements. Compared to racemic amlodipine S-amlodipine caused bigger decrease in systolic and diastolic BP and bigger decrease in daily and 24-hour average diastolic BP after 4 week of therapy.
Conclusion. S-amlodipine is effective antihypertensive drug, showing more significant BP decrease in comparison with this of racemic amlodipine after 4 weeks of treatment.
About the Authors
M. A. Maksimova
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Y. V. Lukina
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
S. N. Tolpygina
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
E. V. Shilova
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
N. A. Dmitrieva
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
S. Y. Martsevich
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
Russian Federation
Department of evidence-based medicine, Moscow Medical Academy named after I.M. Sechenov
References
1. Фельдшерова Н.А., Семернин Е.Н. Амлодипин: обзор клинических ис- следований. Качественная клиническая практика 2002;(2):27-33.
2. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.
3. Dahl f B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.
4. Julius S., Kjeldsen S.E., Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens, based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31.
5. Burges R.A., Gardiner D.G., Gwilt M. et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receceptors. J Cardiovasc Pharmacol 1987;9:110-119.
6. Pathak L, Hiremath, Kerkar PG, Manade VG. Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. J Assoc Physicians India 2004;52:197-202.
7. Kerkar PG. Clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of hypertension. Indian J Clin Pract 2003; 13, 11:49-53.
Review
For citations:
Maksimova M.A., Lukina Y.V., Tolpygina S.N., Shilova E.V., Dmitrieva N.A., Martsevich S.Y. COMPARATIVE STUDY OF EFFICIENCY AND SAFETY OF THE NEW DRUG OF AMLODOPINE – S-AMLODOPINE IN PATIENTS WITH ARTERIAL HYPERTENSION OF I-II DEGREE. Rational Pharmacotherapy in Cardiology. 2008;4(2):34-37. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-2-34-37
Views:
735
.jpg)
Email this article 